Physician profile
Robert Pavelock
NPI 1891777413
$18,681.24
in general payments reported to CMS, 2019-2025
44 companies · $4,113 in 2025
The $4,113 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $248 · 2021: $1,850 · 2022: $3,096 · 2023: $3,267 · 2024: $4,674 · 2025: $4,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,843.67 |
| Education | $210.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,168.51 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $4,049.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,813.37 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $1,378.11 | 2019-2025 | |
| Celgene Corporation | $744.57 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $653.12 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $610.23 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $573.69 | 2019-2024 | Stelara |
| Ardelyx, INC. | $460.72 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $443.39 | 2021-2025 | Vemlidy, Livdelzi |
| Qol Medical, LLC | $298.41 | 2019-2025 | Sucraid, Sucraid |
| Ucb, INC. | $271.82 | 2019-2023 | Cimzia |
| Madrigal Pharmaceuticals | $265.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $259.46 | 2019-2025 | Ocaliva |
| Medtronic, INC. | $249.48 | 2021-2024 | Endoflip, Pillcam, Barrx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246.00 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $208.25 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $180.02 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $173.04 | 2021-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $168.33 | 2023-2025 | Rebyota, Clenpiq |
| Boston Scientific Corporation | $167.90 | 2021-2025 | Jagwire, Spyglass, Wallflex Duodenal |
| Braintree Laboratories, INC. | $129.25 | 2022-2023 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Olympus America INC. | $112.62 | 2024 | Endoclot Phs |
| Celltrion USA INC. | $107.33 | 2024-2025 | Zymfentra, Vegzelma |
| Allergan, INC. | $86.13 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $75.77 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $75.00 | 2022-2023 | |
| Capsovision, INC. | $73.32 | 2024-2025 | Capsocam Plus |
| Genzyme Corporation | $73.30 | 2025 | |
| Fresenius Kabi USA, LLC | $72.63 | 2023-2025 | Adalimumab-Aacf, Idacio |
| Shire North American Group INC | $68.94 | 2019 | |
| Csl Behring | $67.27 | 2023-2025 | Kcentra |
| Phathom Pharmaceuticals, INC. | $40.60 | 2023-2025 | Voquezna |
| Cumberland Pharmaceuticals, INC. | $37.96 | 2024-2025 | Kristalose |
| Organon LLC | $24.19 | 2024-2025 | Hadlima |
| Sun Pharmaceutical Industries INC. | $23.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.50 | 2019 | |
| Novo Nordisk INC | $18.75 | 2023 | Wegovy |
| Fujifilm Healthcare Americas Corporation | $18.50 | 2024 | Fujifilm |
| Axonics, INC. | $16.58 | 2023 | Axonics, Bulkamid |
| Daiichi Sankyo INC. | $14.71 | 2024 | Injectafer |
| Horizon Therapeutics Plc | $12.16 | 2019 | |
| Romark Laboratories, Lc | $2.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pavelock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.